A number of other analysts have also recently weighed in on the stock. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a buy rating to a strong-buy rating in a report on Saturday, August 3rd. Piper Jaffray Companies set a $8.00 price target on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a report on Wednesday, October 9th. SunTrust Banks reiterated a buy rating and issued a $11.00 target price (up from $9.00) on shares of Catalyst Pharmaceuticals in a research note on Thursday, August 8th. Cantor Fitzgerald lifted their target price on shares of Catalyst Pharmaceuticals from $10.00 to $12.00 in a research note on Thursday, August 8th. Finally, Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a hold rating to a buy rating and set a $5.75 target price for the company in a research note on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Catalyst Pharmaceuticals presently has a consensus rating of Buy and an average target price of $8.63.
NASDAQ:CPRX traded up $0.41 during mid-day trading on Tuesday, hitting $5.07. 1,780,200 shares of the company’s stock were exchanged, compared to its average volume of 1,998,751. Catalyst Pharmaceuticals has a one year low of $1.85 and a one year high of $7.67. The company has a market cap of $477.90 million, a PE ratio of -15.36 and a beta of 2.37. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.09 and a quick ratio of 5.07. The business has a fifty day moving average price of $5.18 and a 200 day moving average price of $4.81.
In related news, Director Charles B. O’keeffe bought 10,000 shares of the stock in a transaction that occurred on Friday, October 11th. The stock was bought at an average cost of $4.70 per share, for a total transaction of $47,000.00. Following the purchase, the director now directly owns 553,376 shares of the company’s stock, valued at $2,600,867.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.70% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Creative Planning acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $84,000. Emerald Mutual Fund Advisers Trust acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $5,752,000. Emerald Advisers LLC acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $6,244,000. Finally, California Public Employees Retirement System lifted its stake in Catalyst Pharmaceuticals by 106.8% during the 3rd quarter. California Public Employees Retirement System now owns 136,253 shares of the biopharmaceutical company’s stock valued at $724,000 after acquiring an additional 70,358 shares during the period. Institutional investors and hedge funds own 60.21% of the company’s stock.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.